miRNA29 Ailesi: Diyabetik Nefropatideki Rolleri
Özet
Diyabetik Nefropati (DN), diyabet hastalarının yaklaşık %40'ını etkileyen ve son dönem böbrek yetmezliğinin başlıca nedenlerinden biri olan karmaşık bir klinik tablodur. Geleneksel tanı yöntemlerinin kısıtlılığı, mikroRNA'ların (miRNA) potansiyel biyobelirteçler olarak önemini artırmıştır. Bu moleküller arasında miR29 ailesi (miR29a, b, c), gen ekspresyonunu düzenleyerek hücresel süreçlerde kritik roller üstlenmektedir. miR29 ailesi, özellikle böbrek dokusunda güçlü antifibrotik ve proapoptotik etkiler sergiler. DN patogenezinde, yüksek glukoz ve sitokinlerin etkisiyle miR29 seviyelerindeki değişimler; hücre dışı matriks (ECM) birikimi, podosit hasarı ve enflamasyonla doğrudan ilişkilidir. Çalışmalar, miR29a'nın podosit hasarını azalttığını ve renoprotektif etki sağladığını gösterirken, miR29c'nin renal fibrozun şiddetini belirlemede invaziv olmayan bir biyobelirteç olma potansiyeli taşıdığını vurgulamaktadır. Ayrıca, bu ailenin insülin direnci ve pankreas beta hücre fonksiyonları üzerindeki düzenleyici etkileri, diyabetin sistemik yönetiminde de merkezi bir konumda olduğunu göstermektedir. Gelecekte miRNA tabanlı terapötik müdahaleler ve çoklu belirteç panelleri, DN teşhis ve tedavisinde kişiselleştirilmiş yaklaşımların önünü açacaktır.
Diabetic Nephropathy (DN) is a complex clinical condition affecting approximately 40% of diabetic patients and is a leading cause of end-stage renal disease. The limitations of traditional diagnostic methods have increased the importance of microRNAs (miRNAs) as potential biomarkers. Among these molecules, the miR29 family (miR29a, b, c) plays critical roles in cellular processes by regulating gene expression. The miR29 family exhibits strong antifibrotic and proapoptotic effects, particularly in kidney tissue. In the pathogenesis of DN, alterations in miR29 levels driven by high glucose and cytokines are directly associated with extracellular matrix (ECM) accumulation, podocyte damage, and inflammation. While studies indicate that miR29a reduces podocyte damage and provides renoprotective effects, it is emphasized that miR29c holds potential as a non-invasive biomarker for determining the severity of renal fibrosis. Additionally, the regulatory effects of this family on insulin resistance and pancreatic beta-cell functions demonstrate its central role in the systemic management of diabetes. In the future, miRNA-based therapeutic interventions and multi-marker panels will pave the way for personalized approaches in the diagnosis and treatment of DN.
Referanslar
Lim AK. Diabetic nephropathy – complications and treatment. Int J Nephrol Renov Dis. 2014;7:361-381. doi:10.2147/IJNRD.S40172
Han E, Yun Y, Kim G, et al. Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia. PLOS ONE. 2016;11(5):e0154683. doi:10.1371/journal.pone.0154683
Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4(8):444-452. doi:10.1038/ncpendmet0894
Habib HA, Heeba GH, Khalifa MMA. Comparative effects of incretin-based therapy on early-onset diabetic nephropathy in rats: Role of TNF-α, TGF-β and c-caspase-3. Life Sci. 2021;278:119624. doi:10.1016/j.lfs.2021.119624
Schena FP, Gesualdo L. Pathogenetic Mechanisms of Diabetic Nephropathy. J Am Soc Nephrol. 2005;16(3 suppl 1):S30-S33.
Mogensen CE, Christensen CK, Vittinghus E. The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy. Diabetes. 1983;32(Supplement 2):64-78.doi:10.2337/diab.32.2.S64
O’Bryan GT, Hostetter TH. The renal hemodynamic basis of diabetic nephropathy. Semin Nephrol. 1997;17(2):93-100.
Amy K. M, Katherine R. T, George L. B. Diabetic kidney disease: Manifestations, evaluation, and diagnosis - UpToDate [Internet]. uptodate. [a.yer 04 Mart 2022]. Erişim adresi: https://www.uptodate.com/contents/diabetic-kidney-disease-manifestations-evaluation-and-diagnosis/print?search=diabetic%20nephropathy&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep. 2010;12(5):364-368. doi:10.1007/s11906-010-0133-3
Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, et al. Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab Sci. 2017;54(5):326-342. doi:10.1080/10408363.2017.1377682
Chen X, Zhao L, Xing Y, Lin B. Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression. Biomed Pharmacother. 2018;108:7-14. doi:10.1016/j.biopha.2018.09.007
Conserva F, Barozzino M, Pesce F, et al. Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy. Sci Rep. 2019;9(1):11357. doi:10.1038/s41598-019-47778-1
Kim H, Bae YU, Jeon JS, et al. The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. J Transl Med. 2019;17(1):236. doi:10.1186/s12967-019-1983-3
Nossier AI, Shehata NI, Morsy SM, et al. Determination of certain urinary microRNAs as promising biomarkers in diabetic nephropathy patients using gold nanoparticles. Anal Biochem. 2020;609:113967. doi:10.1016/j.ab.2020.113967
Chien HY, Chen CY, Chiu YH, et al. Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan. Int J Med Sci. 2016;13(6):457-465. doi:10.7150/ijms.15548
Miranda KC, Huynh T, Tay Y, et al. A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes. Cell. 2006;126(6):1203-1217. doi:10.1016/j.cell.2006.07.031
Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835-840. doi:10.1038/nature09267
Baek D, Villén J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455(7209):64-71. doi:10.1038/nature07242
Liu MN, Luo G, Gao WJ, et al. miR-29 family: A potential therapeutic target for cardiovascular disease. Pharmacol Res. 2021;166:105510. doi:10.1016/j.phrs.2021.105510
Lim LP, Lau NC, Weinstein EG, et al. The microRNAs of Caenorhabditis elegans. Genes Dev. 2003;17(8):991-1008. doi:10.1101/gad.1074403
Valencia-Quintana R, Ocampo IUB, Castañeda GG, et al. miRNAs: A potentially valuable tool in pesticide toxicology assessment-current experimental and epidemiological data review. Chemosphere. Published online January 29, 2022:133792. doi:10.1016/j.chemosphere.2022.133792
Wiemer EAC. miRNAs and cancer. J RNAi Gene Silenc Int J RNA Gene Target Res. 2006;2(2):173-174.
Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020;9(2):276. doi:10.3390/cells9020276
Gregory RI, Yan K ping, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235-240. doi:10.1038/nature03120
Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens. 2012;21(4):410-416. doi:10.1097/MNH.0b013e328354e559
Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415-419. doi:10.1038/nature01957
Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A. 2007;104(45):17719-17724. doi:10.1073/pnas.0703890104
Denli AM, Tops BBJ, Plasterk RHA, et al. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231-235. doi:10.1038/nature03049
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509-524. doi:10.1038/nrm3838
Newman MA, Hammond SM. Emerging paradigms of regulated microRNA processing. Genes Dev. 2010;24(11):1086-1092. doi:10.1101/gad.1919710
Iorio MV, Croce CM. MicroRNAs in Cancer: Small Molecules With a Huge Impact. J Clin Oncol. 2009;27(34):5848-5856. doi:10.1200/JCO.2009.24.0317
Kim Y, Yeo J, Lee JH, et al. Deletion of Human tarbp2 Reveals Cellular MicroRNA Targets and Cell-Cycle Function of TRBP. Cell Rep. 2014;9(3):1061-1074. doi:10.1016/j.celrep.2014.09.039
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597-610. doi:10.1038/nrg2843
Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004;116(2):281-297. doi:10.1016/S0092-8674(04)00045-5
Ruiz GP, Camara H, Fazolini NPB, et al. Extracellular miRNAs in redox signaling: Health, disease and potential therapies. Free Radic Biol Med. 2021;173:170-187. doi:10.1016/j.freeradbiomed.2021.05.004
Wang Y, Zhang X, Li H, et al. The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013;92(3):123-128. doi:10.1016/j.ejcb.2012.11.004
Rigoutsos I. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res. 2009;69(8):3245-3248. doi:10.1158/0008-5472.CAN-09-0352
Tay Y, Zhang J, Thomson AM, et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008;455(7216):1124-1128. doi:10.1038/nature07299
Mori MA, Ludwig RG, Garcia-Martin R, et al. Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease. Cell Metab. 2019;30(4):656-673. doi:10.1016/j.cmet.2019.07.011
Iranzad R, Motavalli R, Ghassabi A et al. Roles of microRNAs in renal disorders related to primary podocyte dysfunction. Life Sci. 2021;277:119463. doi:10.1016/j.lfs.2021.119463
Wu KJ. The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness. Biomed J. 2020;43(2):107-114. doi:10.1016/j.bj.2020.03.001
Lagos-Quintana M. Identification of Novel Genes Coding for Small Expressed RNAs. Science. 2001;294(5543):853-858. doi:10.1126/science.1064921
Kriegel AJ, Liu Y, Fang Y, et al. The miR-29 family: Genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012;44(4):237-244. doi:10.1152/physiolgenomics.00141.2011
Lee CC, Ho KH, Huang TW, et al. A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity. Life Sci. 2021;277:119438. doi:10.1016/j.lfs.2021.119438
Zong Y, Yu P, Cheng H, et al. miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer׳s disease. Brain Res. 2015;1624:95-102. doi:10.1016/j.brainres.2015.07.022
Sassi Y, Avramopoulos P, Ramanujam D, et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017;8(1):1614. doi:10.1038/s41467-017-01737-4
Yan Y, Du C, Duan X, et al. Inhibiting collagen I production and tumor cell colonization in the lung via miR-29a-3p loading of exosome-/liposome-based nanovesicles. Acta Pharm Sin B. Published online August 19, 2021. doi:10.1016/j.apsb.2021.08.011
Du Y, Gao C, Liu Z, et al. Upregulation of a Disintegrin and Metalloproteinase With Thrombospondin Motifs-7 by miR-29 Repression Mediates Vascular Smooth Muscle Calcification. Arterioscler Thromb Vasc Biol. 2012;32(11):2580-2588. doi:10.1161/ATVBAHA.112.300206
Kapinas K, Kessler C, Ricks T, et al. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem. 2010;285(33):25221-25231. doi:10.1074/jbc.M110.116137
Wei W, He HB, Zhang WY, et al. miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. Cell Death Dis. 2013;4(6):e668-e668. doi:10.1038/cddis.2013.184
He A, Zhu L, Gupta N, et al. Overexpression of Micro Ribonucleic Acid 29, Highly Up-Regulated in Diabetic Rats, Leads to Insulin Resistance in 3T3-L1 Adipocytes. Mol Endocrinol. 2007;21(11):2785-2794. doi:10.1210/me.2007-0167
Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-11593. doi:10.1158/0008-5472.CAN-06-3613
Dooley J, Garcia-Perez JE, Sreenivasan J, et al. The microRNA-29 Family Dictates the Balance Between Homeostatic and Pathological Glucose Handling in Diabetes and Obesity. Diabetes. 2016;65(1):53-61. doi:10.2337/db15-0770
Hrdlicka HC, Pereira RC, Shin B, et al. Inhibition of miR-29-3p isoforms via tough decoy suppresses osteoblast function in homeostasis but promotes intermittent parathyroid hormone-induced bone anabolism. Bone. 2021;143:115779. doi:10.1016/j.bone.2020.115779
Smith KM, Guerau-de-Arellano M, Costinean S, et al. miR-29ab1 Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. J Immunol. 2012;189(4):1567-1576. doi:10.4049/jimmunol.1103171
Metzinger-Le Meuth V, Metzinger L. miR-223 and other miRNA’s evaluation in chronic kidney disease: Innovative biomarkers and therapeutic tools. Non-Coding RNA Res. 2019;4(1):30-35. doi:10.1016/j.ncrna.2019.01.002
Gholaminejad A, Abdul Tehrani H, Gholami Fesharaki M. Identification of candidate microRNA biomarkers in renal fibrosis: a meta-analysis of profiling studies. Biomarkers. 2018;23(8):713-724. doi:10.1080/1354750X.2018.1488275
Duda P, Akula SM, Abrams SL, et al. GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. Biochim Biophys Acta BBA - Mol Cell Res. 2020;1867(10):118770. doi:10.1016/j.bbamcr.2020.118770
Garzon R, Heaphy CEA, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114(26):5331-5341. doi:10.1182/blood-2009-03-211938
Tan M, Wu J, Cai Y. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun. 2013;438(4):673-679. doi:10.1016/j.bbrc.2013.07.123
Park SY, Lee JH, Ha M, et al. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat Struct Mol Biol. 2009;16(1):23-29. doi:10.1038/nsmb.1533
Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50. doi:10.1038/ng.2007.30
Tsuboi K, Hirayoshi K, Takeuchi K, et al. Expression of the c-myc gene in human gastrointestinal malignancies. Biochem Biophys Res Commun. 1987;146(2):699-704. doi:10.1016/0006-291X(87)90585-7
Muto T, Guillamot M, Yeung J, et al. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022;29(2):298-314.e9. doi:10.1016/j.stem.2021.12.007
Mott JL, Kurita S, Cazanave SC,et al. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem. 2010;110(5):1155-1164. doi:10.1002/jcb.22630
Pandey AK, Verma G, Vig S, et al. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol. 2011;332(1):125-133. doi:10.1016/j.mce.2010.10.004
Shioya M, Obayashi S, Tabunoki H, et al. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol. 2010;36(4):320-330. doi:10.1111/j.1365-2990.2010.01076.x
Lew WYW, Bayna E, Molle ED, et al. Myocardial Fibrosis Induced by Exposure to Subclinical Lipopolysaccharide Is Associated with Decreased miR-29c and Enhanced NOX2 Expression in Mice. PLOS ONE. 2014;9(9):e107556. doi:10.1371/journal.pone.0107556
Long J, Wang Y, Wang W, et al. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 2011;286(13):11837-11848. doi:10.1074/jbc.M110.194969
Zong Y, Wang H, Dong W, et al. miR-29c regulates BACE1 protein expression. Brain Res. 2011;1395:108-115. doi:10.1016/j.brainres.2011.04.035
Cichocki F, Felices M, McCullar V, et al. Cutting Edge: MicroRNA-181 Promotes Human NK Cell Development by Regulating Notch Signaling. J Immunol. 2011;187(12):6171-6175. doi:10.4049/jimmunol.1100835
Saultz JN, Freud AG, Mundy-Bosse BL. MicroRNA regulation of natural killer cell development and function in leukemia. Mol Immunol. 2019;115:12-20. doi:10.1016/j.molimm.2018.07.022
Kang SG, Liu WH, Lu P, et al. MicroRNAs of the miR-17∼92 family are critical regulators of TFH differentiation. Nat Immunol. 2013;14(8):849-857. doi:10.1038/ni.2648
Fayyad-Kazan M, ElDirani R, Hamade E, et al. Circulating miR-29c, miR-30c, miR-193a-5p and miR-885-5p: Novel potential biomarkers for HTLV-1 infection diagnosis. Infect Genet Evol. 2019;74:103938. doi:10.1016/j.meegid.2019.103938
Huang C, Zheng JM, Cheng Q, et al. Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection. J Dig Dis. 2014;15(11):614-621. doi:10.1111/1751-2980.12185
Zhang X, Dong C, Sun X, et al. Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA. Biochem Biophys Res Commun. 2014;450(1):755-761. doi:10.1016/j.bbrc.2014.06.059
Feng Y, Weng H, Ling L, et al. Modulating the gut microbiota and inflammation is involved in the effect of Bupleurum polysaccharides against diabetic nephropathy in mice. Int J Biol Macromol. 2019;132:1001-1011. doi:10.1016/j.ijbiomac.2019.03.242
Tang C, Ou J, Kou L, et al. Circ_016719 plays a critical role in neuron cell apoptosis induced by I/R via targeting miR-29c/Map2k6. Mol Cell Probes. 2020;49:101478. doi:10.1016/j.mcp.2019.101478
Wang R, Li Q, He Y, et al. miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson’s disease. Genes Cells. 2020;25(6):364-374. doi:10.1111/gtc.12764
Kanazawa T, Hamasaki T, Endo T, et al. Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical treatment of atopic dermatitis. Int J Pharm. 2015;489(1):261-267. doi:10.1016/j.ijpharm.2015.05.003
Giridharan S, Srinivasan M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J Inflamm Res. 2018;11:407-419. doi:10.2147/JIR.S140188
Kumari R, Roy U, Desai S, et al. MicroRNA miR-29c regulates RAG1 expression and modulates V(D)J recombination during B cell development. Cell Rep. 2021;36(2):109390. doi:10.1016/j.celrep.2021.109390
Liang J nan, Zou X, Fang X hong, et al. The Smad3-miR-29b/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosis. Biochim Biophys Acta BBA - Mol Basis Dis. 2019;1865(9):2441-2450. doi:10.1016/j.bbadis.2019.06.004
Zhuang M, Chaolumen Q, Li L, et al. MiR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C/GPX1 axis. Biochem Biophys Res Commun. 2020;527(2):511-517. doi:10.1016/j.bbrc.2020.03.170
Huang L, Hu C, Chao H, et al. miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1. Exp Cell Res. 2019;378(1):1-10. doi:10.1016/j.yexcr.2019.02.012
Yao L, Yang L, Song H, et al. MicroRNA miR-29c-3p modulates FOS expression to repress EMT and cell proliferation while induces apoptosis in TGF-β2-treated lens epithelial cells regulated by lncRNA KCNQ1OT1. Biomed Pharmacother. 2020;129:110290. doi:10.1016/j.biopha.2020.110290
Guo J, Li J, Zhao J, et al. MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin. Sci Rep. 2017;7(1):2314. doi:10.1038/s41598-017-01027-5
Batliner J, Jenal M, Fey MF, et al. Mir-29c and Mir-424 Are Novel Myeloid Differentiation-Associated MicroRNAs in Acute Promyelocytic Leukemia. Blood. 2008;112(11):3346. doi:10.1182/blood.V112.11.3346.3346
Zhang JX, Mai SJ, Huang XX, et al. MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of β-catenin signaling. Ann Oncol. 2014;25(11):2196-2204. doi:10.1093/annonc/mdu439
Shang J, Yao Y, Fan X, et al. miR-29c-3p promotes senescence of human mesenchymal stem cells by targeting CNOT6 through p53–p21 and p16–pRB pathways. Biochim Biophys Acta BBA - Mol Cell Res. 2016;1863(4):520-532. doi:10.1016/j.bbamcr.2016.01.005
Wang CM, Wang Y, Fan CG, et al. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2011;411(3):586-592. doi:10.1016/j.bbrc.2011.06.191
Bhatt K, Mi QS, Dong Z. microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am J Physiol-Ren Physiol. 2011;300(3):F602-F610. doi:10.1152/ajprenal.00727.2010
Roggli E, Gattesco S, Caille D, et al. Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes. 2012;61(7):1742-1751. doi:10.2337/db11-1086
Bagge A, Clausen TR, Larsen S, et al. MicroRNA-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. Biochem Biophys Res Commun. 2012;426(2):266-272. doi:10.1016/j.bbrc.2012.08.082
Song H, Ding L, Zhang S, et al. MiR-29 family members interact with SPARC to regulate glucose metabolism. Biochem Biophys Res Commun. 2018;497(2):667-674. doi:10.1016/j.bbrc.2018.02.129
Ghafouri-Fard S, Taheri M. The expression profile and role of non-coding RNAs in obesity. Eur J Pharmacol. 2021;892:173809. doi:10.1016/j.ejphar.2020.173809
Ortega FJ, Moreno-Navarrete JM, Pardo G, et al. MiRNA Expression Profile of Human Subcutaneous Adipose and during Adipocyte Differentiation. PLOS ONE. 2010;5(2):e9022. doi:10.1371/journal.pone.0009022
Yang WM, Jeong HJ, Park SY, et al. Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. FEBS Lett. 2014;588(13):2170-2176. doi:10.1016/j.febslet.2014.05.011
Sun Y, Zhou Y, Shi Y, et al. Expression of miRNA-29 in Pancreatic β Cells Promotes Inflammation and Diabetes via TRAF3. Cell Rep. 2021;34(1):108576. doi:10.1016/j.celrep.2020.108576
Gray CW, Coster ACF. From insulin to Akt: Time delays and dominant processes. J Theor Biol. 2020;507:110454. doi:10.1016/j.jtbi.2020.110454
Wang P, Liu S, Zhu C, et al. MiR-29 regulates the function of goat granulosa cell by targeting PTX3 via the PI3K/AKT/mTOR and Erk1/2 signaling pathways. J Steroid Biochem Mol Biol. 2020;202:105722. doi:10.1016/j.jsbmb.2020.105722
Rong W, Yang L, Li CY, et al. MiR-29 inhibits neuronal apoptosis in rats with cerebral infarction through regulating Akt signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(2):843-850. doi:10.26355/eurrev_202001_20068
Lee IS, Park KC, Yang KJ, et al. Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice. Obes Res Clin Pract. 2016;10(3):315-326. doi:10.1016/j.orcp.2015.07.011
Tang X, Muniappan L, Tang G, et al. Identification of glucose-regulated miRNAs from pancreatic β cells reveals a role for miR-30d in insulin transcription. RNA. 2009;15(2):287-293. doi:10.1261/rna.1211209
Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res. 2013;100(1):7-18. doi:10.1093/cvr/cvt161
Zhang A, Li D, Liu Y, et al. Islet β cell: An endocrine cell secreting miRNAs. Biochem Biophys Res Commun. 2018;495(2):1648-1654. doi:10.1016/j.bbrc.2017.12.028
Calle P, Hotter G. Macrophage Phenotype and Fibrosis in Diabetic Nephropathy. Int J Mol Sci. 2020;21(8):E2806. doi:10.3390/ijms21082806
Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primer. 2017;3(1):1-24. doi:10.1038/nrdp.2017.88
Edeling M, Ragi G, Huang S, et al. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12(7):426-439. doi:10.1038/nrneph.2016.54
Fiserova B, Kubiczkova L, Sedlarikova L, et al. The miR-29 family in hematological malignancies. Biomed Pap. 2015;159(2):184-191. doi:10.5507/bp.2014.037
Deshpande SD, Putta S, Wang M, et al. Transforming Growth Factor-β–Induced Cross Talk Between p53 and a MicroRNA in the Pathogenesis of Diabetic Nephropathy. Diabetes. 2013;62(9):3151-3162. doi:10.2337/db13-0305
Jiang L, Zhou v, Xiong M, et al. Sp1 mediates microRNA-29c-regulated type I collagen production in renal tubular epithelial cells. Exp Cell Res. 2013;319(14):2254-2265. doi:10.1016/j.yexcr.2013.06.007
Du B, Ma LM, Huang MB, et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 2010;584(4):811-816. doi:10.1016/j.febslet.2009.12.053
Meng XM, Tang PMK, Li J, et al. TGF-β/Smad signaling in renal fibrosis. Front Physiol. 2015;6:82. doi:10.3389/fphys.2015.00082
Liu SC, Bamodu OA, Kuo KT, et al. Adipose-derived stem cell induced-tissue repair or wound healing is mediated by the concomitant upregulation of miR-21 and miR-29b expression and activation of the AKT signaling pathway. Arch Biochem Biophys. 2021;705:108895. doi:10.1016/j.abb.2021.108895
Chun-yan L, Zi-yi Z, Tian-lin Y, et al. Liquid biopsy biomarkers of renal interstitial fibrosis based on urinary exosome. Exp Mol Pathol. 2018;105(2):223-228. doi:10.1016/j.yexmp.2018.08.004
Lv LL, Cao YH, Ni HF, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol-Ren Physiol. 2013;305(8):F1220-F1227. doi:10.1152/ajprenal.00148.2013
Fang Y, Yu X, Liu Y, et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation. Am J Physiol-Ren Physiol. 2013;304(10):F1274-F1282. doi:10.1152/ajprenal.00287.2012
Li H, Zhu X, Zhang J, et al. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway. Biomed Pharmacother. 2017;96:471-479. doi:10.1016/j.biopha.2017.10.019
Lee HW, Khan SQ, Khaliqdina S, et al. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1*. J Biol Chem. 2017;292(2):732-747. doi:10.1074/jbc.M116.753822
Chen C, Zhu D, Zhang S, et al. Identification of circRNA/miRNA/mRNA regulatory network involving (+)-catechin ameliorates diabetic nephropathy mice. Food Sci Hum Wellness. 2022;11(3):660-668. doi:10.1016/j.fshw.2021.12.023
Yang Y, Xiao L, Li J, et al. Urine miRNAs: Potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses. 2013;81(2):274-278. doi:10.1016/j.mehy.2013.04.031
Fan WX, Wen XL, Xiao H, et al. MicroRNA-29a enhances autophagy in podocytes as a protective mechanism against high glucose-induced apoptosis by targeting heme oxygenase-1. Eur Rev Med Pharmacol Sci. 2018;22(24):8909-8917. doi:10.26355/eurrev_201812_16660
Lin CL, Lee PH, Hsu YC, et al. MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction. J Am Soc Nephrol JASN. 2014;25(8):1698-1709. doi:10.1681/ASN.2013050527
Hasslacher C, ed. Diabetic Nephropathy. Wiley; 2001.
Nemecz M, Alexandru N, Tanko G, et al. Role of MicroRNA in Endothelial Dysfunction and Hypertension. Curr Hypertens Rep. 2016;18(12):87. doi:10.1007/s11906-016-0696-8
Cantero-Navarro E, Fernández-Fernández B, Ramos AM, et al. Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021;529:111254. doi:10.1016/j.mce.2021.111254
Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol-Cell Physiol. 2007;292(1):C82-C97. doi:10.1152/ajpcell.00287.2006
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. N Engl J Med. 2001;345(12):851-860. doi:10.1056/NEJMoa011303
Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993;44(3):545-550. doi:10.1038/ki.1993.279
Li J, Yang T, Sha Z, et al. Angiotensin II-induced muscle atrophy via PPARγ suppression is mediated by miR-29b. Mol Ther - Nucleic Acids. 2021;23:743-756. doi:10.1016/j.omtn.2020.12.015
Sun L, Zhang J, Li Y. Chronic central miR-29b antagonism alleviates angiotensin II-induced hypertension and vascular endothelial dysfunction. Life Sci. 2019;235:116862. doi:10.1016/j.lfs.2019.116862
Zhang Y, Huang XR, Wei LH, Cet al. miR-29b as a Therapeutic Agent for Angiotensin II-induced Cardiac Fibrosis by Targeting TGF-β/Smad3 signaling. Mol Ther. 2014;22(5):974-985. doi:10.1038/mt.2014.25
Kemp JR, Unal H, Desnoyer R, et al. Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin–angiotensin system. J Mol Cell Cardiol. 2014;75:25-39. doi:10.1016/j.yjmcc.2014.06.008
